Adults with type 2 diabetes who switched from basal insulin therapy to insulin glargine injection experienced similar numbers of hypoglycemia events and decreases in average HbA1c as those who switched to insulin degludec.
Real-World Data Shows Similar Rate of Hypoglycemia Events With Insulin Glargine Injection, Insulin Degludec
In patients with HER2-positive metastatic gastric cancer, subcutaneous administration of a common therapy results in significant time savings for health care providers as well as reduced costs.
A single-agent therapy conferred a favorable safety profile and exhibited evidence of durable responses in patients with heavily pretreated relapsed and refractory multiple myeloma.
A 21-gene assay poses an overall incremental cost increase to the health care system in the short-term, despite lower rates of chemotherapy use.
Elderly patients with acute myeloid leukemia faced high health care costs in their first year following diagnosis.
Patients with sickle cell disease who are insured through Medicaid used hematology care services at a far lower rate than commercially insured patients.
Hospice use among multiple myeloma patients at the end of life has steadily increased over time.
The FDA has given full approval to a drug for the treatment of adults with a recurrent type of brain cancer that has progressed following prior therapy.
The National Comprehensive Cancer Network recently released updated guidelines for the treatment of cancer-related infections, fever, neutropenia, and other adverse events.
A psoriasis drug is now approved to treat psoriatic arthrits in adults.